Holen Sie sich die Stockscreener-App
0.8674
4.12%
0.0343
Schlusskurs vom Vortag:
$0.8331
Offen:
$0.8342
24-Stunden-Volumen:
427.89K
Relative Volume:
0.16
Marktkapitalisierung:
$12.91M
Einnahmen:
$3,000
Nettoeinkommen (Verlust:
$-7.78M
KGV:
-0.8384
EPS:
-1.0346
Netto-Cashflow:
$-7.49M
1W Leistung:
+0.90%
1M Leistung:
-14.12%
6M Leistung:
-32.23%
1J Leistung:
-62.29%
1-Tages-Spanne:
$0.81
$0.8674
1-Wochen-Bereich:
$0.7765
$0.9151
52-Wochen-Spanne:
$0.7765
$2.45
Biocardia Inc Stock (BCDA) Company Profile
Firmenname
Biocardia Inc
Sektor
Branche
Telefon
650-226-0123
Adresse
320 SOQUEL WAY, SUNNYVALE, CA
Compare BCDA vs MOBBW, SHMD, GOODO, PSNYW, DWLD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| 0.41 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
2.45 | 3.33B | 0 | 0 | 0 | 0.00 |
SHMD
Schmid Group N V
|
6.19 | 397.06M | 52.15M | -21.46M | 0 | -0.4675 |
GOODO
Gladstone Commercial Corporation
|
20.19 | 372.90M | 0 | 0 | 0 | 0.00 |
PSNYW
Polestar Automotive Holding Uk
|
2.83 | 254.39M | 2.07B | -1.42B | -1.37B | -0.6765 |
DWLD
Davis Select Worldwide ETF
|
47.19 | 0 | 0 | 0 | 0 | 0.00 |
Biocardia Inc Stock (BCDA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-04-16 | Herabstufung | Dawson James | Buy → Neutral |
Biocardia Inc Aktie (BCDA) Neueste Nachrichten
BioCardia Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
BioCardia (NASDAQ: BCDA) raises $4.9M and updates Nasdaq listing compliance - Stock Titan
BioCardia shares rally after FDA supports regulatory path for heart failure therapy (BCDA) - MSN
BCDA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
BioCardia CEO Peter Altman buys $4,250 in company stock - Investing.com
BioCardia (BCDA) CEO Peter Altman adds 5,000 shares in open-market buy - Stock Titan
Why did BCDA stock surge more than 50% today? - MSN
BioCardia's $4.4M Lifeline: Fuel for Japan, But For How Long? - BriefGlance
Biocardia raises $4.5 million through share sale By Investing.com - Investing.com Nigeria
BioCardia Announces $4.4 Million Financing to Extend Cash Runway Into 2027 and Support Japan PMA Submission 9 - Minichart
Biocardia raises $4.5 million through share sale - Investing.com
BioCardia, Inc. Raises $4.48 Million to Extend Cash Runway into 2027 Ahead of PMDA Submission - Quiver Quantitative
BioCardia Announces $4.4 Million Financing - The Manila Times
BioCardia sells 3.51M shares for $4.49M to extend cash runway into early 2027 - TradingView
BioCardia (NASDAQ: BCDA) extends cash runway with $4.4M equity raise - Stock Titan
BCDA Stock Surges As FDA Softens Trial Requirements For CardiAMP - timothysykes.com
BioCardia Company Profile & Introduction - Moomoo
BCDA Surges As BioCardia Wins Key FDA Trial Backing - StocksToTrade
Why Is BioCardia Stock Gaining Friday? - Sahm
BCDA Surges As BioCardia Wins FDA PMA Pathway Nod - timothysykes.com
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
$BioCardia (BCDA.US)$ all in all..got a good trade..big profits..but thats all for now..gl all - Moomoo
BioCardia (BCDA) Advances CardiAMP Cell Therapy Approval Process - GuruFocus
BioCardia Jumps After FDA Feedback Seen Positive for CardiAMP Approval - TechStock²
BioCardia jumps after FDA minutes clarify PMA path for CardiAMP HF II trial - Quiver Quantitative
$BioCardia (BCDA.US)$ 🚀🚀🚀 - Moomoo
BioCardia Shares Rally After FDA Supports Regulatory Path for Heart Failure Therapy (BCDA) - Yahoo Finance
BioCardia’s CardiAMP HF II Clinical Trial May Support FDA Premarket Approval for Cell Therapy in Heart Failure - Minichart
BCDA Stock Jumps As FDA Clears Path For Helix Catheter - StocksToTrade
$BioCardia (BCDA.US)$ - Moomoo
BCDA Stock Holds Key Support As FDA Clears Paths For Helix - timothysykes.com
BioCardia stock surges on FDA trial pathway confirmation By Investing.com - Investing.com India
BioCardia stock surges on FDA trial pathway confirmation - Investing.com
BioCardia receives FDA feedback on heart failure trial pathway By Investing.com - Investing.com India
BioCardia receives FDA feedback on heart failure trial pathway - Investing.com
BioCardia® Receives FDA Minutes Confirming Eligibility for Premarket Approval of CardiAMP Cell Therapy for Ischemic Heart Failure - Quiver Quantitative
FDA Confirms CardiAMP HF II May Support Premarket Approval of CardiAMP Cell Therapy for Ischemic HFrEF - The Manila Times
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
FDA minutes support BioCardia (NASDAQ: BCDA) CardiAMP HF II PMA pathway - Stock Titan
FDA flags heart failure cell therapy trial that may aid 1M patients - Stock Titan
BioCardia outlines Japan Shonin filing in ~7 months and targets ~19-month path to approval for CardiAMP - MSN
BCDA Stock Price, Quote & Chart | BIOCARDIA INC (NASDAQ:BCDA) - ChartMill
BioCardia receives regulatory guidance from Japan’s PMDA - Investing.com UK
BioCardia receives regulatory guidance from Japan’s PMDA By Investing.com - Investing.com South Africa
BioCardia, Inc. (BCDA) Files 8-K with SEC: Company Details, Stock Info, and Contact Information (May 28, 2026) - Minichart
Finanzdaten der Biocardia Inc-Aktie (BCDA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Biocardia Inc-Aktie (BCDA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Altman Peter | President and CEO |
May 20 '26 |
Buy |
0.92 |
1,500 |
1,380 |
293,266 |
| Altman Peter | President and CEO |
May 19 '26 |
Buy |
0.95 |
200 |
190 |
291,766 |
| Altman Peter | President and CEO |
May 18 '26 |
Buy |
0.92 |
5,700 |
5,244 |
291,566 |
| Altman Peter | President and CEO |
May 15 '26 |
Buy |
1.02 |
5,100 |
5,202 |
285,866 |
| Altman Peter | President and CEO |
Apr 29 '26 |
Buy |
1.11 |
5,000 |
5,550 |
280,766 |
| Altman Peter | President and CEO |
Apr 20 '26 |
Buy |
1.23 |
600 |
738 |
275,366 |
| Altman Peter | President and CEO |
Apr 21 '26 |
Buy |
1.23 |
400 |
492 |
275,766 |
| Altman Peter | President and CEO |
Mar 24 '26 |
Buy |
1.24 |
600 |
744 |
274,466 |
| Altman Peter | President and CEO |
Mar 25 '26 |
Buy |
1.22 |
300 |
366 |
274,766 |
| Altman Peter | President and CEO |
Feb 04 '26 |
Buy |
1.13 |
5,000 |
5,650 |
273,866 |
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):